Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 247 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ITCH Clear all
Completed Phase 2 Interventional Results available

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

NCT04365387
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 54 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
64
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 8:30 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

NCT02229929
View directory record Official record
Conditions
Pruritus, Uremic Pruritus
Interventions
Part A: Placebo, Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg, Part A: CR845 2.5 mcg/kg, Part B: Placebo, Part B: CR845 1.0 mcg/kg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Pine Bluff, Arkansas • Chula Vista, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jun 10, 2026, 8:30 AM EDT
Withdrawn No phase listed Observational

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

NCT01801670
View directory record Official record
Conditions
Pruritus
Interventions
Biopsy, Blood
Procedure
Lead sponsor
Boston University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

NCT03123471
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jun 10, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
Tricalm Hydrogel, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Jun 10, 2026, 8:30 AM EDT
Completed No phase listed Observational

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

NCT01679015
View directory record Official record
Conditions
Dry Eyes, Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
Schwartz Laser Eye Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 10, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

NCT06736262
View directory record Official record
Conditions
Urticaria Chronic
Interventions
Briquilimab
Drug
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593
View directory record Official record
Conditions
Tinea Pedis
Interventions
TA103, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

NCT05363449
View directory record Official record
Conditions
Tinea Cruris, Tinea Pedis
Interventions
UHE-103 Cream, Naftin (naftifine hydrochloride) Cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
San Diego, California • Thousand Oaks, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jun 10, 2026, 8:30 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

NCT00914186
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TS022, Vehicle
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
La Jolla, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jun 10, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic

NCT06226610
View directory record Official record
Conditions
Pruritis
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Akron Children's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

NCT02174419
View directory record Official record
Conditions
Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions
nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

NCT05030311
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

The CO2RE® System for Vulvar Lichen Sclerosus

NCT04148651
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
The CO2RE® System
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

NCT05393076
View directory record Official record
Conditions
Pruritus
Interventions
Linerixibat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Phase 3 Interventional Results available

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

NCT05093478
View directory record Official record
Conditions
Non-allergic Rhinitis
Interventions
Intranasal capsaicin, topical lidocaine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jun 10, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Cooling Pillow for Atopic Dermatitis

NCT01132651
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Current standard eczema treatment and standard pillow at night, Chillow cooling pillow
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Jun 10, 2026, 8:30 AM EDT